{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-012816","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.373225+00:00","generated_at":"2026-06-12T11:51:14.756217+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"GlycoMimetics Q2 cash $58M; uproleselan Phase 3 topline by Q2 2024; GMI-1687 Phase 1a in Q3","bullets":["Cash $58.0M at June 30, 2023, up from $47.9M at Dec 31, 2022; R&D spend $4.1M, down 49% YoY.","Pivotal Phase 3 uproleselan R/R AML topline results expected by end of Q2 2024 after time-based analysis amendment.","FDA agreed to initial Pediatric Study Plan; NCI will sponsor Phase 1/2 uproleselan study in pediatric AML.","First pediatric patient dosed in investigator-initiated Phase 1/2 study of uproleselan with pre-transplant conditioning.","GMI-1687 (E-selectin antagonist) Phase 1a study in healthy volunteers to initiate in Q3 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-012816","json":"https://secwatch.observer/filing/0001558370-23-012816.json","markdown":"https://secwatch.observer/filing/0001558370-23-012816.md","text":"https://secwatch.observer/filing/0001558370-23-012816.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023012816/0001558370-23-012816-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023012816/glyc-20230802x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T11:51:14.756217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9e9bef874eb3de48c24dbde2baeb8e905b8d613c","claim":"CRESCENT BIOPHARMA, INC. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 2, 2023, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023012816/0001558370-23-012816-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}